Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Pantoprazole 20 mg gastro-resistant tablet

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Pantoprazole sodium sesquihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Pantoprazole sodium sesquihydrate

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for 2. What you need to know before you take Pantoprazole 3. How to take Pantoprazole 4. Possible side effects 5. How to store Pantoprazole 6. Contents of the pack and other information

Adults and adolescents 12 years of age and above:

  • Treating symptoms (e.g. heartburn, acid regurgitation, pain on swallowing) associated to gastro-oesophageal reflux disease caused by reflux of acid from the stomach.
  • Long-term management of reflux oesophagitis (inflammation of the oesophagus accompanied by the regurgitation of stomach acid) and preventing its return. Adults:
  • Preventing duodenal and stomach ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs, for example, ibuprofen) in patients at risk who need to take NSAIDs continuously.

What you need to know before you take it

e Pantoprazole Do not take Pantoprazole

  • If you are allergic to pantoprazole, sorbitol or any of the other ingredients of this medicine (listed in section 6).
  • If you are allergic to medicines containing other proton pump inhibitors. Warnings and precautions Talk to your doctor or pharmacist or nurse before taking Pantoprazole.

smer vlaken/direction on fibre

70 mm ± 0,5 mm

111

  • If you have severe liver problems. Please tell your doctor if you have ever had problems with your liver. Your doctor will check your liver enzymes more frequently, especially when you are taking Pantoprazole as a long-term treatment. In the case of a rise of liver enzymes the treatment should be stopped.
  • If you need to take medicines called NSAIDs continuously and receive Pantoprazole because you have an increased risk of developing stomach and intestinal complications. Any increased risk will be assessed according to your own personal risk factors such as your age (65 years old or more), a history of stomach or duodenal ulcers or of stomach or intestinal bleeding.
  • If you have reduced body stores or risk factors for reduced vitamin B12 and receive long-term treatment with pantoprazole. As with all acid reducing agents, pantoprazole may lead to a reduced absorption of vitamin B12.
  • If you are taking HIV protease inhibitors such as atazanavir (for the treatment of HIV-infection) at the same time as pantoprazole, ask your doctor for specific advice.
  • Taking a proton pump inhibitor like pantoprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine.
  • Tell your doctor if you have osteoporosis (reduced bone density) or if you have been told that you are at risk of getting osteoporosis (for example, if you are taking steroids).
  • If you are on Pantoprazole for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of

520 mm ± 0,8 mm

magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.

  • If you have ever had a skin reaction after treatment with a medicine similar to Pantoprazole that reduces stomach acid.
  • If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with Pantoprazole. Remember to also mention any other ill-effects like pain in your joints.
  • You are due to have a specific blood test (Chromogranin A). Tell your doctor immediately if you notice any of the following symptoms:
  • an unintentional loss of weight
  • vomiting, particularly if repeated
  • vomiting blood; this may appear as dark coffee grounds in your vomit
  • you notice blood in your stools; which may be black or tarry in appearance
  • difficulty in swallowing or pain when swallowing
  • you look pale and feel weak (anaemia)
  • chest pain
  • stomach pain
  • severe and/or persistent diarrhoea, as Pantoprazole has been associated with a small increase in infectious diarrhoea. Your doctor may decide that you need some tests to rule out malignant disease because pantoprazole also alleviates the symptoms of cancer and could cause delay in diagnosing it. If your symptoms continue in spite of your treatment, further investigations will be considered.

If you take Pantoprazole on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You should report any new and exceptional symptoms and circumstances whenever you see your doctor. This medicine may affect the way that your body absorbs vitamin B12, particularly if you need to take it for a long time. Please contact your doctor if you notice any of the following symptoms, which could indicate low levels of Vitamin B12:

  • extreme tiredness or lack of energy
  • pins and needles
  • sore or red tongue, mouth ulcers
  • muscle weakness
  • disturbed vision
  • problems with memory, confusion, depression. Children and adolescents These tablets are not recommended for use in children below 12 years. Other medicines and Pantoprazole Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pantoprazole may influence the effectiveness of other medicines, so tell your doctor if you are taking
  • Medicines such as ketoconazole, itraconazole and posaconazole (used to treat fungal infections) or erlotinib (used for certain types of cancer) because Pantoprazole may stop these and other medicines from working properly.
  • Warfarin and phenprocoumon, which affect the thickening, or thinning of the blood. You may need further checks.
  • Medicines used to treat HIV-infection, such as atazanavir.
  • Methotrexate (used to treat rheumatoid arthritis, psoriasis and cancer)- if you are taking methotrexate your doctor may temporarily stop your Pantoprazole treatment because pantoprazole can increase levels of methotrexate in the blood.

70 mm ± 0,5 mm

  • Fluvoxamine (used to treat depression and other psychiatric diseases) – if you are taking fluvoxamine your doctor may reduce the dose.
  • Rifampicin (used to treat infections).
  • St John's wort (Hypericum perforatum) (used to treat mild depression). Pantoprazole with food and drink Take the tablets 1 hour before a meal without chewing or breaking them and swallow them whole with some water. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. There are no adequate data from the use of pantoprazole in pregnant women. Excretion into human milk has been reported. You should use this medicine only if your doctor considers the benefit for you greater than the potential risk for your unborn child or baby. Driving and using machines Pantoprazole has no or negligible influence on the ability to drive and use machines. If you experience side effects like dizziness or disturbed vision, you should not drive or operate machines. Pantoprazole contains sorbitol and sodium. This medicine contains 18 mg sorbitol in each tablet. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

How to take it

Pantoprazole Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

:ffl

smer branja kode/direction of reading PhC

When and how should you take Pantoprazole? Take the tablets 1 hour before a meal without chewing or breaking them and swallow them whole with some water. Unless told otherwise by your doctor, the recommended dose is: Adults and adolescents 12 years of age and above: To treat symptoms (e.g. heartburn, acid regurgitation, pain on swallowing) associated to gastro-oesophageal reflux disease The recommended dose is one tablet a day. This dose usually brings relief within 2 – 4 weeks – at most after another 4 weeks. Your doctor will tell you how long to continue taking the medicine. After this any recurring symptoms can be controlled by taking one tablet daily, when required. For long-term management and for preventing the return of reflux oesophagitis The recommended dose is one tablet a day. If the illness returns, your doctor can double the dose, in which case you can use Pantoprazole 40 mg tablets instead, one a day. After healing, you can reduce the dose back again to one tablet 20 mg a day. Adults: To prevent duodenal and stomach ulcers in patients who need to take NSAIDs continuously The recommended dose is one tablet a day. Special patient groups:

  • If you suffer from severe liver problems, you should not take more than one 20 mg tablet a day. Use in children and adolescents Children below 12 years. These tablets are not recommended for use in children below 12 years.

Leaflet folded on middle with visibly first side (title); PhC that comes out of the middle of leaflet must be visible!/ Navodila prepognjena na sredini z vidno prvo stranjo (naslovom); pharma kodi, ki izhajata iz sredine navodila, morata biti vidni!

  • Črna U/Black U iKRKk Šifra/Article No.: XXXXXX Emb. mat./Article name.: NA./PL. Pantoprazole 20 mg gastro-resistant tablets GB Dimenzije/Dimension: 148 ± 0,5 mm x 520 ± 0,8 mm Material: papir tip B/Woodfree paper 50 g/m2 PhC št./PhC No.: 4543 Merilo/Measure: 1:1 Datum/Date: 19.06.2023 Izdelal/Prepared by:

Oddelek za oblikovanje/Packaging Design MockUp014398_1

If you take more Pantoprazole than you should Tell your doctor or pharmacist. There are no known symptoms of overdose. If you forget to take Pantoprazole Do not take a double dose to make up for a forgotten dose. Take your next normal dose at the usual time. If you stop taking Pantoprazole Do not stop taking these tablets without first talking to your doctor or pharmacist. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

148 mm ± 0,5 mm

4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get any of the following side effects, stop taking these tablets and tell your doctor immediately, or contact the casualty department at your nearest hospital: Serious allergic reactions (frequency rare (may affect up to 1 in 1,000 people)):

  • swelling of the tongue and/or throat,
  • difficulty in swallowing,
  • hives (nettle rash),
  • difficulties in breathing,
  • allergic facial swelling (Quincke's oedema / angioedema),
  • severe dizziness with very fast heartbeat and heavy sweating. Serious skin conditions (frequency not known (frequency cannot be estimated from the available data)): you may notice one or more of the following:
  • blistering of the skin and rapid deterioration of your general condition,

smer branja kode/direction of reading PhC

130 mm ± 0,5 mm

  • erosion (including slight bleeding) of eyes, nose, mouth/lips or genitals or skin sensitivity/rash, particularly in areas of skin exposed to light/the sun.
  • You may also have joint pain or flu-like symptoms, a fever, swollen glands (e.g. in the armpit) and blood tests may show changes in certain white blood cells or liver enzymes (Stevens-Johnson-Syndrome, Lyell Syndrome, Erythema multiforme, Subacute cutaneous lupus erythematosus, Drug reaction with eosinophilia and systemic symptoms (DRESS), Photosensitivity). Other serious conditions (frequency not known (frequency cannot be estimated from the available data)):
  • yellowing of the skin or whites of the eyes (severe damage to liver cells, jaundice) or
  • fever,
  • rash, and
  • enlarged kidneys sometimes with painful urination and lower back pain (serious inflammation of the kidneys, possibly progressing to kidney failure). Other side effects are: Common (may affect up to 1 in 10 people)
  • Benign polyps in the stomach. Uncommon (may affect up to 1 in 100 people)
  • Headache;
  • dizziness;
  • diarrhoea;
  • feeling sick, vomiting;
  • bloating and flatulence (wind);
  • constipation;
  • dry mouth;
  • abdominal pain and discomfort;
  • skin rash, exanthema, eruption;
  • itching;
  • fracture of the hip, wrist or spine;
  • feeling weak, exhausted or generally unwell;
  • sleep disorders. Rare (may affect up to 1 in 1,000 people)
  • Disturbances in vision such as blurred vision;
  • hives;
  • pain in the joints;
  • muscle pains;
  • weight changes;
  • raised body temperature;
  • high fever;
  • swelling of the extremities (peripheral oedema);
  • allergic reactions;
  • depression;
  • breast enlargement in males;
  • distortion or complete lack of the sense of taste. Very rare (may affect up to 1 in 10,000 people)
  • Disorientation. Not known (frequency cannot be estimated from the available data)
  • Hallucination, confusion (especially in patients with a history of these symptoms);
  • feeling of tingling, prickling, pins and needles, burning sensation or numbness;
  • inflammation in the large bowel, that causes persistent watery diarrhoea;
  • rash, possibly with pain in the joints.

Possible side effects

identified through blood tests: Uncommon (may affect up to 1 in 100 people)

  • An increase in liver enzymes. Rare (may affect up to 1 in 1,000 people)
  • An increase in bilirubin;
  • increased fats in the blood.
  • Sharp drop in circulating granular white blood cells, associated with high fever

Blister pack: Store in the original package in order to protect from moisture.

A plastic container of 100 and 250 gastro-resistant tablets.

Very rare (may affect up to 1 in 10,000 people)

  • A reduction in the number of blood platelets, which may cause you to bleed or bruise more than normal;
  • A reduction in the number of white blood cells, which may lead to more frequent infections;
  • Coexisting abnormal reduction in the number of red and white blood cells, as well as platelets

Container: Keep the container tightly closed in order to protect from moisture. After first opening of the container, the product should be used within 3 months.

Marketing Authorisation Holder KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Not known (frequency cannot be estimated from the available data)

  • Decreased level of sodium, magnesium, calcium or potassium in blood (see section 2). Reporting of side effects If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme, Website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Pantoprazole Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

Not all pack sizes may be marketed.

Manufacturer KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, D-27472 Cuxhaven, Germany This leaflet was last revised in 06/2023.

What Pantoprazole contains

  • The active substance is pantoprazole. Each gastro-resistant tablet contains 20 mg pantoprazole (as pantoprazole sodium sesquihydrate).
  • The other ingredients are mannitol, crospovidone (type A, type B), sodium carbonate, sorbitol (E420), calcium stearate in the tablet core and hypromellose, povidone (K25), titanium dioxide (E171), yellow iron oxide (E172), propylene glycol, methacrylic acid – ethyl acrylate copolymer, sodium laurilsulfate, polysorbate 80, macrogol 6000 and talc in the film-coating.
  • See section 2 "Pantoprazole contains sorbitol and sodium". What Pantoprazole looks like and contents of the pack The 20 mg gastro-resistant tablets are light brownish yellow, oval, slightly biconvex tablets. Pack sizes: Cartons of 7, 14, 15, 20, 28, 30, 50, 50 x 1, 56, 60, 84, 90, 98, 100, 100 x 1, 112 and 140 gastro-resistant tablets in blister packs.

XXXXXX

NA./PL. Pantoprazole 20 mg gastro-resistant tablets GB druga stran/second page

III smer vlaken/direction on fibre

520 mm ± 0,8 mm

130 mm ± 0,5 mm

smer branja kode/direction of reading PhC

Frequently asked questions about Pantoprazole 20 mg gastro-resistant tablet

How do I take Pantoprazole 20 mg gastro-resistant tablet?

Pantoprazole 20 mg gastro-resistant tablet comes as tablet containing 20mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Pantoprazole 20 mg gastro-resistant tablet?

The active substance in Pantoprazole 20 mg gastro-resistant tablet is pantoprazole sodium sesquihydrate.

Are there equivalent medicines to Pantoprazole 20 mg gastro-resistant tablet?

Medicines with the same active substance, strength and form include: Pantoprazole 20 mg gastro-resistant tablets, Pantoprazole 20 mg gastro-resistant tablets, Pantoprazole 20mg Gastro-resistant Tablets. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Pantoprazole 20 mg gastro-resistant tablet, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Pantoprazole 20 mg gastro-resistant tablet without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Pantoprazole sodium sesquihydrate (12 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

4.2. Posology and method of administration

Posology

The recommended dose is 20 mg pantoprazole (one tablet) per day.

It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. Once complete relief of symptoms has occurred, treatment should be discontinued. The treatment should not exceed 4 weeks without consulting a doctor.

If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.

Special populations

No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function.

Paediatric population

Pantoprazole Krka is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy.

Method of administration

Pantoprazole Krka 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, nelfinavir; due to significant reduction in their bioavailability(see section 4.5).

4.4. Special warnings and precautions for use

Patients should be instructed to consult a doctor if:

- They have unintentional weight loss, anaemia, gastrointestinal bleeding, dysphagia, persistent vomiting or vomiting with blood, since pantoprazole may alleviate symptoms and delay diagnosis of a severe condition. In these cases, malignancy should be excluded.

- They have had previous gastric ulcer or gastrointestinal surgery.

- They are on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks.

- They have jaundice, hepatic impairment, or liver disease.

- They have any other serious disease affecting general well-being.

- They are aged over 55 years with new or recently changed symptoms.

Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals. Especially, patients over 55 years taking any non-prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor.

Patients should not take another proton pump inhibitor or H2 antagonist concomitantly.

Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test.

Patients should be advised that the tablets are not intended to provide immediate relief.

Patients may start to experience symptomatic relief after approximately one day of treatment with pantoprazole, but it might be necessary to take it for 7 days to achieve complete heartburn control. Patients should not take pantoprazole as a preventive medicinal product.

Gastrointestinal infections caused by bacteria

Decreased gastric acidity, due to any means - including proton pump inhibitors - increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with acidreducing medicinal products leads to a slightly increased risk of gastrointestinal infections such as Salmonella, Campylobacter, or C. difficile.

Subacute cutaneous lupus erythematosus (SCLE)

Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Pantoprazole Krka. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.

Interference with laboratory tests

Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Pantoprazole Krka treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.

This medicinal product is intended for short-term use (up to 4 weeks) only (Refer to section 4.2). Patients should be warned about additional risks with long-term use of the medicinal products and the need for prescription and regular surveillance should be emphasized.

The following additional risks are considered relevant for long-term use:

Influence on vitamin B12 absorption:

Pantoprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.

Bone Fracture:

Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in older people or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10–40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.

Hypomagnesemia:

Severe hypomagnesaemia has been rarely reported in patients treated with proton pump inhibitors (PPIs) like pantoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness, and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. Hypomagnesaemia may lead to hypocalcaemia and/or hypokalaemia (see section 4.8). In most affected patients, hypomagnesaemia (and hypomagnesaemia associated hypocalcaemia and/or hypokalaemia) improved after magnesium replacement and discontinuation of the PPI.

For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.

Pantoprazole Krka contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.

4.5. Interaction with other medicinal products and other forms of interaction

Medical products with pH dependent absorption pharmacokinetics

Pantoprazole Krka may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole).

HIV protease inhibitors:

Co-administration of pantoprazole is contraindicated with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, nelfinavir; due to significant reduction in their bioavailability(see section 4.3).

Coumarin anticoagulants (phenoprocoumon or warfarin)

Although no interaction during concomitant administration of phenprocoumon or warfarin has been observed in clinical pharmacokinetic studies, a few isolated cases of changes in International Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing period. Therefore, in patients treated with coumarin anticoagulants (e.g. phenprocoumon or warfarin), monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular use of pantoprazole.

Methotrexate

Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example caner and psoriasis, a temporary withdrawal of pantoprazole may need to be considered

Other interactions studies

Pantoprazole is metabolized in the liver via the cytochrome P450 enzyme system. Interaction studies with carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, naproxen, nifedipine, phenytoin, piroxicam, theophylline and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions. However, an interaction of pantoprazole with other substances which are metabolised by the same enzyme system cannot be excluded.

There were no interactions with concomitantly administered antacids.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no adequate data from the use of pantoprazole in pregnant women. Studies in animals have shown reproductive toxicity. Preclinical studies revealed no evidence of impaired fertility or teratogenic effects (see section 5.3). The potential risk for humans is unknown. Pantoprazole should not be used during pregnancy.

Breast-feeding

Pantoprazole/metabolites have been identified in human milk. The effect of pantoprazole on newborns/infants is unknown. Pantoprazole Krka should not be used during breast-feeding.

Fertility

There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3).

4.7. Effects on ability to drive and use machines

Pantoprazole Krka has no or negligible influence on the ability to drive and use machines. However adverse reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or use machines.

4.8. Undesirable effects

Summary of the safety profile

Approximately 5% of patients can be expected to experience adverse reactions.

Tabulated list of adverse reactions

The following adverse reactions have been reported with pantoprazole.

Within the following table, adverse reactionsare ranked under the MedDRA frequency classification: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data)

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 1. Undesirable effects with pantoprazole in clinical trials and post-marketing experience

Frequency System Organ Class

Common

Uncommon

Rare

Very rare

Not known

Blood and lymphatic system disorders

Agranulocytosis

Thrombocytopenia;

Leucopenia;

Pancytopenia

Hallucination;

Immune system disorders

Hypersensitivity (including anaphylactic reactions and anaphylactic shock)

Metabolism and nutrition disorders

Hyperlipidaemias and lipid increases (triglycerides, cholesterol);

Weight changes

Hyponatraemia;

Hypomagnesaemia

Hypocalcaemia(1)

Hypokalaemia(1)

Psychiatric disorders

Sleep disorders

Depression (and all aggravations)

Disorientation (and all aggravations)

Hallucination;

Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)

Nervous system disorders

Headache;

Dizziness

Taste disorders

Eye disorders

Disturbances in vision / blurred vision

Gastrointestinal disorders

Fundic gland polyps (benign)

Diarrhoea;

Nausea / vomiting;

Abdominal distension and bloating;

Constipation;

Dry mouth;

Abdominal pain and discomfort

Microscopic colitis

Hepatobiliary disorders

Liver enzymes increased (transaminases, γ-GT)

Bilirubin increased

Hepatocellular injury;

Jaundice;

Hepatocellular failure

Skin and subcutaneous tissue disorders

Rash / exanthema / eruption;

Pruritus

Urticaria;

Angioedema

Stevens-Johnson syndrome;

Lyell syndrome;

Erythema multiforme;

Drug reaction with eosinophilia and systemic symptoms (DRESS)

Photosensitivity;

Subacute cutaneous lupus erythematosus (see section 4.4)

Musculoskeletal, connective tissue disorders

Fracture of wrist, hip and spine

Arthralgia;

Myalgia

Renal and urinary disorders

Interstitial nephritis

Reproductive system and breast disorders

Gynaecomastia

General disorders and administration site conditions

Asthenia, fatigue and malaise

Body temperature increased;

Oedema peripheral

(1) Hypocalcaemia and/or hypokalaemia may be related to the occurrence of hypomagnesaemia (see section 4.4)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms

There are no known symptoms of overdose in man.

Doses up to 240 mg administered intravenously over 2 minutes were well tolerated.

Management

As pantoprazole is extensively protein bound, it is not readily dialysable.

In the case of overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.

💬 Ask about this leaflet

Ask anything about Pantoprazole 20 mg gastro-resistant tablet. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →